The senior director of biomarker sciences at a major pharma company speaks to how their company currently invests today, experiences ROI, and expects investments to change in the future. They have responsibilities in assay development, assay validation, and data delivery for both oncology and rare diseases. Today, they see the greatest investments in research tools, particularly liquid biopsy, as well as bioinformatics. They feel that bioinformatic investments yield strong ROIs by allowing easier collaborations, but its true potential is to be determined. On the whole, they feel that investments in biobanking have been the most rewarding and enabling of translational research. They feel that real world evidence has a cap on its ROI; their organization would like to invest in it more readily, but the data that is available often does not include all the fields they need. The most prominent pain points are issues around IP and how that plays into navigating relationships with vendors and accessing data. Other trends that will impact how this expert’s organization invests relate the use of MRD and monitoring technologies, emerging therapeutic modalities such as ADCs, and also the use of AI or other advanced bioinformatics.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.